Critical Contrast: Intellia Therapeutics (NASDAQ:NTLA) vs. Neurogene (NASDAQ:NGNE)
by Tristan Rich · The Markets DailyIntellia Therapeutics (NASDAQ:NTLA – Get Free Report) and Neurogene (NASDAQ:NGNE – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.
Earnings & Valuation
This table compares Intellia Therapeutics and Neurogene”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Intellia Therapeutics | $59.51 million | 26.40 | -$412.69 million | ($3.36) | -3.34 |
| Neurogene | $930,000.00 | 506.70 | -$90.35 million | ($5.03) | -4.68 |
Neurogene has lower revenue, but higher earnings than Intellia Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 11.7% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Intellia Therapeutics and Neurogene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intellia Therapeutics | -672.16% | -57.79% | -47.29% |
| Neurogene | N/A | -45.10% | -41.00% |
Analyst Recommendations
This is a breakdown of recent recommendations for Intellia Therapeutics and Neurogene, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intellia Therapeutics | 5 | 8 | 9 | 1 | 2.26 |
| Neurogene | 1 | 0 | 5 | 2 | 3.00 |
Intellia Therapeutics presently has a consensus price target of $20.72, suggesting a potential upside of 84.81%. Neurogene has a consensus price target of $80.29, suggesting a potential upside of 240.92%. Given Neurogene’s stronger consensus rating and higher possible upside, analysts plainly believe Neurogene is more favorable than Intellia Therapeutics.
Risk and Volatility
Intellia Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500.
Summary
Neurogene beats Intellia Therapeutics on 9 of the 14 factors compared between the two stocks.
About Intellia Therapeutics
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
About Neurogene
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.